Artivion outlines 2026 revenue growth target of 10% to 14% with strong AMDS and On-X momentum [Seeking Alpha]
Artivion, Inc. (AORT)
Company Research
Source: Seeking Alpha
CEO James Mackin described 2025 as "a highly successful year for Artivion," noting "meaningful progress against our strategy designed to drive long-term growth, profitable growth through our expanding and clinically differentiated product portfolio." He highlighted Quick Insights Key growth drivers include strong stent graft and On-X sales, AMDS and NEXUS regulatory progress, market expansion, and new product launches, with additional benefits from ongoing clinical evidence and operational investments. Management is confident based on expanding product adoption, robust clinical data, successful new product accounts, and plans for EBITDA to grow at twice the constant-currency revenue rate, but analysts continue to focus on execution, especially for AMDS and On-X. Risks include the impact of government payback legislation, manufacturing inefficiencies, lingering effects of a cybersecurity incident on tissue revenues, the pace of AMDS adoption, and maintaining high growth rates
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Artivion Inc (AORT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges [Yahoo! Finance]Yahoo! Finance
- Artivion (NYSE:AORT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $51.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- Artivion (AORT) Stock Trades Down, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Artivion Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
AORT
Earnings
- 2/12/26 - Beat
AORT
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/12/26 - Form 8-K
- 1/28/26 - Form 5
- AORT's page on the SEC website